|
|
|
|
|
Highlights from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium
|
|
|
|
|
| PSMA-Based Therapy in Advanced Disease: Touching on Combination Sequencing
|
| Devaki S. Surasi, MBBS, CMQ
|
| Dr. Devaki Surasi presented on combination sequencing for PSMA-based therapy in advanced disease. Dr. Surasi started with a case of a 74 year old with mCRPC status post ADT, 6 cycles of docetaxel, enzalutamide, and palliative radiotherapy to the prostate, the right clavicle, and L3/L4.
|
|
|
|
|
|
| Seeing Is Believing: Radiographic Criteria to Assess Response
|
| Danny M. Cortes, MD
|
| Dr. Danny Cortes presented on radiographic criteria to assess response to radioligand therapy. Currently, theranostics relies on molecular imaging based selection criteria. In VISION, this was a visual approach: >= 1 PSMA-positive lesions anywhere in the body (uptake > liver). In TheraP, this required an SUVmax > 20. Dr. Cortes notes that we see is what we treat, and we treat is what we see.
|
|
|
|
|
|
| Overall Survival and Quality of Life with 177Lu-PSMA-617 plus Enzalutamide Versus Enzalutamide Alone in Poor-Risk mCRPC in ENZA-P (ANZUP 1901)
|
| Louise Emmett, MD, MBChB, FRACP, FAANMS
|
| Dr. Louise Emmett presented overall survival and quality of life in ENZA-p with 177Lu-PSMA-617 (LuPSMA) plus enzalutamide versus enzalutamide alone in poor-risk, mCRPC.
|
|
|
|
|
|
| COBRA: Assessment of the Efficacy of 64Cu-SAR-bisPSMA Using Histopathology as Reference Standard in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy
|
| Luke Nordquist, MD
|
| Dr. Luke Nordquist presented on COBRA, an assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.
|
|
|
|
|
|
|
|
|
|
|
| Real-World Treatment Patterns and Outcomes in Advanced Prostate Cancer: A Cohort Study Using the Prostate Cancer Disease Observation (PRECISION) Data Platform
|
| Elisabeth I. Heath, MD, FACP
|
| Dr. Elisabeth Heath presented real-world treatment patterns and outcomes in advanced prostate cancer from the PRECISION data platform. There are several real-world data sources for prostate cancer, each with its own limitations, the most notable of which is an incomplete picture of the multidisciplinary clinical management of prostate cancer.
|
|
|
|
|
|
| Real-World Outcomes Among Patients with mCRPC Receiving Guideline-Recommended Therapies After Treatment with 177Lu-PSMA-617: A Real-World Prostate Cancer Disease Observation (PRECISION) Data Platform Analysis
|
| Xiao X. Wei, MD, MAS
|
| Dr. Xiao Wei presented an analysis of the PRECISION data platform assessing real-world outcomes among patients with mCRPC receiving guideline-recommended therapies after treatment with 177Lu-PSMA-617.
|
|
|
|
|
|
| Relationship Between Undetectable PSA Nadir and Outcomes for Patients with mHSPC in IRONMAN, the International Registry for Men with Advanced Prostate Cancer
|
| Hannah McManus, MD
|
| Dr. Hannah McManus presented on Relationship between undetectable PSA nadir and outcomes for patients with mHSPC in IRONMAN, the International Registry for Men with Advanced Prostate Cancer.
|
|
|
|
|
|
| Optyx Study: Clinical Characteristics and Preferences for Initiating Relugolix in a Cohort of US Patients in Real-World Care Settings
|
| Daniel Spratt, MD
|
| Dr. Daniel Spratt presented the Optyx study: Clinical characteristics and preferences for initiating relugolix in a cohort of US patients in real-world care settings. OPTYX was a multicenter observational study that enrolled men with prostate cancer initiating relugolix across various disease stages and treatment regimens, including monotherapy and combination therapy.
|
|
|
|
|
|
|
|
|
|
|
| Real-World Comparison of Cabazitaxel vs. 177-Lutetium-PSMA Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer
|
| Mike Wenzel, MD
|
| Dr. Mike Wenzel presented Real-world comparison of cabazitaxel vs. 177-lutetium-PSMA radioligand therapy in metastatic castration resistant prostate cancer. He began his presentation by stating that ¹⁷⁷Lu-PSMA therapy is under extensive scientific investigation and is increasingly becoming an established standard of care for mCRPC.
|
|
|
|
|
|
| Cancer-Control Outcomes of Metastatic Castration Resistant Prostate Cancer Patients with BRCA-Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium PSMA Radioligand Therapy
|
| Mike Wenzel, MD
|
| Dr. Mike Wenzel presented on Cancer-control outcomes of mCRPC patients with BRCA-gene or tumor suppressor mutations undergoing 177-lutetium PSMA radioligand therapy. There are several tumor gene mutations known for mCRPC. However, the individual response to ¹⁷⁷Lu-PSMA therapy is under investigation and is likely associated with the genomic profile of mCRPC patients.
|
|
|
|
|
|
| Lutetium-177 PSMA Radioligand Therapy in Taxane-Naïve First- and Second-Line Metastatic Castration Resistant Prostate Cancer After First-Line ARPI Therapy
|
| Philipp Mandel, MD
|
| Dr. Philipp Mandel presented on Lutetium-177 PSMA radioligand therapy in taxane-naïve first- and second-line mCRPC after first-line ARPI therapy. He began his presentation by highlighting that Lu-PSMA radioligand therapy has been approved by the EMA for treating mCRPC in the third line setting, after progression on an ARPI and taxane-based chemotherapy. However, its effect on taxane-naïve patients remains under investigation.
|
|
|
|
|
|
| Survival Outcomes of Patients with mCRPC Receiving Lutetium-177-PSMA-617 (Lu) Based on Line of Therapy
|
| Nicolas Sayegh, MD
|
| Dr. Nicolas Sayegh presented Abstract 82: Survival outcomes of patients with mCRPC receiving lutetium-177-PSMA-617 (Lu) based on line of therapy. He began his presentation by highlighting that ¹⁷⁷Lutetium is a PSMA-targeted radiopharmaceutical that delivers beta radiation to PSMA-expressing cells.
|
|
|
|
|
|
| Real World Outcomes of 177Lu-PSMA-617 in a Racially Diverse Cohort of Patients with mCRPC
|
| Margo Gerke
|
| Margo Gerke presented real world outcomes of 177Lu-PSMA-617 in a racially diverse cohort of patients with mCRPC. ¹⁷⁷Lu-PSMA-617 is approved for the treatment of mCRPC based on the VISION trial. However, despite enrolling patients across 84 centers in nine countries in North America and Europe, the trial had limited racial diversity with only 6.6% total enrollment of Black or African American patients.
|
|
|
|
|
|
